From dirty drugs to hyperselectivity and part way back again

Human Psychopharmacology

Volumn 12, Issue SUPPL. 3, 1997, Pages

  Briley, M ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Milnacipran; Monoamine reuptake; Pharmacokinetics; Pharmacology; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ANTICHOLINERGIC EFFECT; BEHAVIOR; BRAIN; CARDIOTOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; IN VITRO STUDY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030883667     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199709)12:3+3.0.CO;2-H     Document Type: Conference Paper

References (30)

1. Anderson, I. M. and Tomenson, B. M. (1994). The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 8, 238-249.
2. Assié, M. B., Charvéron, M., Palmier, C., Puozzo, C., Moret, C. and Briley, M. (1992). Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology, 31, 149-155.
3. Assié, M. B., Le Lann, A. D., Stenger, A. and Briley, M. (1990). Repeated administration of milnacipran, a new antidepressant, has no effect on a functional beta-adrenergic response in the rat brain. European Journal of Pharmacology, 183, 741-742.
4. 3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain. Brain Research, 668, 129-143.
5. Blier, P., Weiss, M. and De Montigny, C. (1992). Effects of sustained administration of milnacipran on serotonin and noradrenaline neurotransmissions in rat hippocampus [abstract]. In Symposium on the Role of Serotonin in Psychiatric Disorders, Castres: 9. Castres, Pierre Fabre Research Centre.
6. Danish University Antidepressant Group. (1986). Citalopram: a clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology, 90, 131-138.
7. Danish University Antidepressant Group. (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. Journal of Affective Disorders, 18, 289-299.
8. DeVane, C. L. (1994). Pharmacokinetics of the newer antidepressants: clinical relevance. American Journal of Medicine, 97 (Suppl 6A), 13S-23S.
9. Feighner, J. P. and Boyer, W. F. (1993). Selective Serotonin Re-uptake Inhibitors: the Clinical Use of Citalopram, Fluoxetine, Fluvoxamine, Paroxetine and Sertraline. Perspectives in Psychiatry, Volume 1. John Wiley, Chichester.
10. Güthert, M., Huth, H. and Schlicker, E. (1981). Characterization of the receptor subtype involved in alpha adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Nauyn Schmiedeberg's Archives of Pharmacology, 317, 199-203.
11. Hall, H. and Ögren, S-O. (1981). Effects of antidepressant drugs on different receptors in the brain. European Journal of Pharmacology, 70, 393-407.
12. Kanof, P. D. and Greengard, P. (1978). Brain histamine receptors as targets for antidepressant drugs. Nature, 272, 329-333.
13. Lacroix, P., Rocher, N., Gandon, J. M. and Panconi, E. (1995). Antidepressant effects of milnacipran in the learned helplessness test in rats. European College of Neuropsychopharmacology, Venice abstract.
14. Lecrubier, Y. (1997). Milnacipran: the clinical properties of an SNRI. Human Psychopharmacology, 12, 00-00.
15. Montgomery, S. A. and Kasper, S. (1995). Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology, 9 (Suppl 4), 33-40.
16. Montgomery, S. A., Prost, J. F., Solles, A. and Briley, M. (1996). Efficacy and tolerability of milnacipran: an overview. International Clinical Psychopharmacology, 11 (Suppl 4): 47-51.
17. Moret, C. and Briley, M. (1990). Serotonin autoreceptor subsensitivity and antidepressant activity. European Journal of Pharmacology, 180, 351-356.
18. Moret, C. and Briley, M. (1992). Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology, 31, 679-684.
19. Moret, C. and Briley, M. (1994). Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. Progress in Neuropharmacology, Biology and Psychiatry, 18, 1063-1072.
20. Moret, C. and Briley, M. (1996). In vivo study of monoamines neurotransmission by milnacipran, a double noradrenaline and serotonin reuptake inhibiting antidepressant. Brain Research Association Abstracts, 13, 35 [abstract].
21. Moret, C., Charvéron, M., Finberg, J. P. M., Couzinier, J. P. and Briley, M. (1985). Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology, 24, 1211-1219.
22. Neliat, G., Bodinier, M-C., Panconi, E. and Briley, M. (1996). Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the α-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology, 35, 589-593.
23. Nelson, J. C., Mazure, C. M., Bowers, M. B. and Jatlow, P. I. (1991). A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry, 48, 303-307.
24. Potter, W. Z., Rudorfer, M. V. and Manji, H. (1991). The pharmacologie treatment of depression. New England Journal of Medicine, 325, 633-642.
25. Puozzo, C. and Leonard, B. E. (1996). Pharmacokinetics of milnacipran in comparison with other antidepressants. International Clinical Psychopharmacology, 11 (Suppl 4): 15-27.
26. Puozzo, C., Rostin, M., Montastruc, J. L. and Houin, G. (1987). Absolute bioavailability study of midalcipran (F2207) in volunteers. In Proceedings: European Congress of Biopharmaceutics and Pharmacokinetics, Aiache J. M., Hirtz J. (Eds.), University of Clermont-Ferrand, Clermont-Ferrand, pp. 59-68.
27. Redmond, A. M., Kelly, J. P. and Leonard, B. E. (1995). The behavioural effects of milnacipran in the olfactory bulbectomised rat model of depression. Medical Science Research, 23, 533-534.
28. Stenger, A., Couzinier, J. P. and Briley, M. (1987). Psychopharmacology of midalcipran, 1-phenyl-1-diethylaminocarbonyl-2-aminomethyl-cyclopropane hydrochloride (F2207), a new potential antidepressant. Psychopharmacology, 91, 149-153.
29. Sulser, F. (1983). Mode of action of antidepressant drugs. Journal of Clinical Psychiatry, 44, 14-20.
30. Thomas, D. R., Nelson, D. R. and Johnson, A. M. (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.